Cargando…

Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy

Background: The piracetam analog, aniracetam, has recently received attention for its cognition enhancing potential, with minimal reported side effects.  Previous studies report the drug to be effective in both human and non-human models with pre-existing cognitive dysfunction, but few studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Conner D., Jefferson, Taylor S., Volquardsen, Meagan, Pandian, Ashvini, Smith, Gregory D., Holley, Andrew J., Lugo, Joaquin N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998011/
https://www.ncbi.nlm.nih.gov/pubmed/29946420
http://dx.doi.org/10.12688/f1000research.11023.3
_version_ 1783331165711630336
author Reynolds, Conner D.
Jefferson, Taylor S.
Volquardsen, Meagan
Pandian, Ashvini
Smith, Gregory D.
Holley, Andrew J.
Lugo, Joaquin N.
author_facet Reynolds, Conner D.
Jefferson, Taylor S.
Volquardsen, Meagan
Pandian, Ashvini
Smith, Gregory D.
Holley, Andrew J.
Lugo, Joaquin N.
author_sort Reynolds, Conner D.
collection PubMed
description Background: The piracetam analog, aniracetam, has recently received attention for its cognition enhancing potential, with minimal reported side effects.  Previous studies report the drug to be effective in both human and non-human models with pre-existing cognitive dysfunction, but few studies have evaluated its efficacy in healthy subjects. A previous study performed in our laboratory found no cognitive enhancing effects of oral aniracetam administration 1-hour prior to behavioral testing in naïve C57BL/6J mice. Methods: The current study aims to further evaluate this drug by administration of aniracetam 30 minutes prior to testing in order to optimize any cognitive enhancing effects. In this study, all naïve C57BL/6J mice were tested in tasks of delayed fear conditioning, novel object recognition, rotarod, open field, elevated plus maze, and marble burying. Results: Across all tasks, animals in the treatment group failed to show enhanced learning when compared to controls. Conclusions: These results provide further evidence suggesting that aniracetam conveys no therapeutic benefit to subjects without pre-existing cognitive dysfunction.
format Online
Article
Text
id pubmed-5998011
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-59980112018-06-25 Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy Reynolds, Conner D. Jefferson, Taylor S. Volquardsen, Meagan Pandian, Ashvini Smith, Gregory D. Holley, Andrew J. Lugo, Joaquin N. F1000Res Research Article Background: The piracetam analog, aniracetam, has recently received attention for its cognition enhancing potential, with minimal reported side effects.  Previous studies report the drug to be effective in both human and non-human models with pre-existing cognitive dysfunction, but few studies have evaluated its efficacy in healthy subjects. A previous study performed in our laboratory found no cognitive enhancing effects of oral aniracetam administration 1-hour prior to behavioral testing in naïve C57BL/6J mice. Methods: The current study aims to further evaluate this drug by administration of aniracetam 30 minutes prior to testing in order to optimize any cognitive enhancing effects. In this study, all naïve C57BL/6J mice were tested in tasks of delayed fear conditioning, novel object recognition, rotarod, open field, elevated plus maze, and marble burying. Results: Across all tasks, animals in the treatment group failed to show enhanced learning when compared to controls. Conclusions: These results provide further evidence suggesting that aniracetam conveys no therapeutic benefit to subjects without pre-existing cognitive dysfunction. F1000 Research Limited 2018-06-22 /pmc/articles/PMC5998011/ /pubmed/29946420 http://dx.doi.org/10.12688/f1000research.11023.3 Text en Copyright: © 2018 Reynolds CD et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Reynolds, Conner D.
Jefferson, Taylor S.
Volquardsen, Meagan
Pandian, Ashvini
Smith, Gregory D.
Holley, Andrew J.
Lugo, Joaquin N.
Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
title Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
title_full Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
title_fullStr Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
title_full_unstemmed Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
title_short Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
title_sort oral aniracetam treatment in c57bl/6j mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998011/
https://www.ncbi.nlm.nih.gov/pubmed/29946420
http://dx.doi.org/10.12688/f1000research.11023.3
work_keys_str_mv AT reynoldsconnerd oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy
AT jeffersontaylors oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy
AT volquardsenmeagan oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy
AT pandianashvini oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy
AT smithgregoryd oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy
AT holleyandrewj oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy
AT lugojoaquinn oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy